Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) EBITDA (2020 - 2025)

Historic EBITDA for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$4.8 million.

  • Gain Therapeutics' EBITDA fell 732.93% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 1797.26%. This contributed to the annual value of -$20.4 million for FY2024, which is 854.95% up from last year.
  • Latest data reveals that Gain Therapeutics reported EBITDA of -$4.8 million as of Q3 2025, which was down 732.93% from -$5.1 million recorded in Q2 2025.
  • Gain Therapeutics' 5-year EBITDA high stood at -$2.5 million for Q1 2021, and its period low was -$8.2 million during Q2 2024.
  • For the 5-year period, Gain Therapeutics' EBITDA averaged around -$4.7 million, with its median value being -$4.6 million (2022).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 56005.52% in 2021, then surged by 3780.23% in 2025.
  • Quarter analysis of 5 years shows Gain Therapeutics' EBITDA stood at -$3.2 million in 2021, then crashed by 42.15% to -$4.6 million in 2022, then grew by 3.38% to -$4.4 million in 2023, then rose by 24.42% to -$3.3 million in 2024, then plummeted by 43.67% to -$4.8 million in 2025.
  • Its EBITDA stands at -$4.8 million for Q3 2025, versus -$5.1 million for Q2 2025 and -$4.4 million for Q1 2025.